| 1 |
34268956 | Efficacy of trastuzumab combined with SOX or IP chemotherapy regimen in the treatment of advanced gastric cancer. | 2021 May-Jun |
2 |
| 2 |
32503654 | Does a ketogenic diet as an adjuvant therapy for drug treatment enhance chemotherapy sensitivity and reduce target lesions in patients with locally recurrent or metastatic Her-2-negative breast cancer? Study protocol for a randomized controlled trial. | 2020 Jun 5 |
1 |
| 3 |
31466383 | Quantifying Risk Pathway Crosstalk Mediated by miRNA to Screen Precision drugs for Breast Cancer Patients. | 2019 Aug 28 |
1 |
| 4 |
28526406 | Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models. | 2017 Jul 8 |
1 |
| 5 |
28850174 | Chemotherapy for advanced gastric cancer. | 2017 Aug 29 |
1 |
| 6 |
25601188 | Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer. | 2015 Mar |
3 |
| 7 |
25885574 | A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol. | 2015 Feb 21 |
1 |
| 8 |
25890497 | The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. | 2015 May 10 |
2 |
| 9 |
26439663 | Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates. | 2015 Dec 28 |
3 |
| 10 |
26634139 | CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2-neu-positive breast cancer. | 2015 Apr |
2 |
| 11 |
22124996 | Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B. | 2013 Apr |
1 |
| 12 |
22973964 | Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models. | 2013 |
1 |
| 13 |
23852648 | A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5). | 2013 Aug |
1 |
| 14 |
22213294 | Trastuzumab has opposing effects on SN-38-induced double-strand breaks and cytotoxicity in HER2-positive gastric cancer cells depending on administration sequence. | 2012 Jan |
1 |
| 15 |
22389470 | HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer. | 2012 Apr |
3 |
| 16 |
23335549 | Electrolyte abnormalities due to irinotecan administration in metastatic HER-2 positive breast cancer patients. | 2012 Oct-Dec |
1 |
| 17 |
21868346 | [Efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen in the treatment of HER2-positive advanced gastric cancer]. | 2011 Aug |
1 |
| 18 |
21985855 | Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T). | 2011 |
1 |
| 19 |
20238327 | Chemotherapy for advanced gastric cancer. | 2010 Mar 17 |
1 |
| 20 |
19461176 | [Evaluation of irinotecan hydrochloride (CPT-11) and trastuzumab combination therapy as salvage treatment in patients with HER2 overexpressing metastatic breast cancer]. | 2009 May |
3 |
| 21 |
15641483 | Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. | 2004 |
2 |